Identification

Name
Acepromazine
Accession Number
DB01614
Type
Small Molecule
Groups
Approved, Vet approved
Description

Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.

Structure
Thumb
Synonyms
  • 1-[10-(3-DIMETHYLAMINO-propyl)-10H-phenothiazin-2-yl]-ethanone
  • 10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone
  • 10-(3-dimethylaminopropyl)phenothiazine-3-ethylone
  • Acetazine
  • Acetopromazine
  • Acetylpromazine
Product Ingredients
IngredientUNIICASInChI Key
Acepromazine maleate37862HP2OM3598-37-6FQRHOOHLUYHMGG-BTJKTKAUSA-N
International/Other Brands
Acezine 2 / Atravet
Categories
UNII
54EJ303F0R
CAS number
61-00-7
Weight
Average: 326.456
Monoisotopic: 326.145284026
Chemical Formula
C19H22N2OS
InChI Key
NOSIYYJFMPDDSA-UHFFFAOYSA-N
InChI
InChI=1S/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3
IUPAC Name
1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethan-1-one
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O

Pharmacology

Indication

Acepromazine was first used in humans in the 1950s as an antipsychotic agent. It is now rarely used in humans. Acepromazine is frequently used in animals as a sedative and antiemetic. Its principal value is in quietening and calming anxious animals.

Pharmacodynamics

Acepromazine is one of the phenothiazine derivative psychotropic drugs. Acepromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Acepromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.

Mechanism of action

Acepromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 1A
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

3 hours in horses.

Clearance
Not Available
Toxicity

Agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineAcepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAcepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineAcepromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAcepromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineAcepromazine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Acepromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Acepromazine is combined with 7-Nitroindazole.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
AceprometazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Acepromazine is combined with Adipiplon.Investigational
AdrafinilAcepromazine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineAcepromazine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Acepromazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Acepromazine.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Acepromazine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Acepromazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Acepromazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Acepromazine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmibegronAcepromazine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
AmisulprideAcepromazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazAcepromazine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Acepromazine.Approved
AmlodipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Acepromazine.Approved, Illicit
AmodiaquineThe serum concentration of Acepromazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the antihypertensive activities of Acepromazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amperozide.Experimental
AmphetamineAcepromazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Acepromazine is combined with Amrinone.Approved
AnisodamineAcepromazine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineAcepromazine may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineAcepromazine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Aranidipine.Approved, Investigational
ArbutamineAcepromazine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolAcepromazine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Acepromazine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Acepromazine.Investigational
ArtemetherThe serum concentration of Acepromazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Acepromazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Acepromazine can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Acepromazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Acepromazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Articaine.Approved
AsenapineAsenapine may increase the antihypertensive activities of Acepromazine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
AtovaquoneThe serum concentration of Acepromazine can be increased when it is combined with Atovaquone.Approved
AvanafilAvanafil may increase the hypotensive activities of Acepromazine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Azaperone.Investigational, Vet Approved
AzelastineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Acepromazine is combined with Azimilide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Acepromazine.Approved
BambuterolAcepromazine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Acepromazine.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Acepromazine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Acepromazine.Approved, Investigational
BenzphetamineAcepromazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Acepromazine is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of hypotension can be increased when Acepromazine is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Acepromazine.Approved
BezitramideAcepromazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe risk or severity of hypotension can be increased when Acepromazine is combined with Bioallethrin.Approved, Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
BitolterolAcepromazine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
BrexpiprazoleAcepromazine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Acepromazine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Acepromazine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acepromazine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Acepromazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Acepromazine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Acepromazine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Acepromazine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Acepromazine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
BuprenorphineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Acepromazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Acepromazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Acepromazine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Acepromazine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Acepromazine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Acepromazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Acepromazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Acepromazine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Acepromazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Acepromazine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Acepromazine is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Acepromazine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Acepromazine.Approved
CaroverineThe risk or severity of hypotension can be increased when Acepromazine is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Acepromazine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Acepromazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Acepromazine.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Acepromazine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Acepromazine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Acepromazine.Approved
ChloroquineThe serum concentration of Acepromazine can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acepromazine.Approved
ChlorphentermineAcepromazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Acepromazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineChlorpromazine may increase the antihypertensive activities of Acepromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acepromazine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Acepromazine.Approved
CilnidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Cilnidipine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Acepromazine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Acepromazine is combined with Cinnarizine.Approved, Investigational
CirazolineAcepromazine may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Acepromazine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Acepromazine.Approved, Investigational
ClenbuterolAcepromazine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Acepromazine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Acepromazine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Acepromazine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Acepromazine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Acepromazine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Acepromazine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Acepromazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clothiapine.Experimental
ClozapineClozapine may increase the antihypertensive activities of Acepromazine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Acepromazine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Acepromazine.Approved, Illicit
CyclandelateThe risk or severity of hypotension can be increased when Acepromazine is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Acepromazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine.Approved
Cycloguanil embonateThe serum concentration of Acepromazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Acepromazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Acepromazine.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Acepromazine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Acepromazine.Investigational
DapsoneThe serum concentration of Acepromazine can be increased when it is combined with Dapsone.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Darodipine.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Acepromazine.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Acepromazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acepromazine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acepromazine.Approved, Vet Approved
DextroamphetamineAcepromazine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acepromazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Acepromazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Acepromazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Acepromazine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Acepromazine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Acepromazine is combined with Diethyl ether.Experimental
DiethylpropionAcepromazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Acepromazine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acepromazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acepromazine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Acepromazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acepromazine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Acepromazine is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Acepromazine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acepromazine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Acepromazine.Approved, Illicit
DipivefrinAcepromazine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Acepromazine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dixyrazine.Experimental
DL-MethylephedrineAcepromazine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineAcepromazine may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineAcepromazine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Acepromazine is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of hypotension can be increased when Acepromazine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Acepromazine.Approved
DoxepinDoxepin may increase the antihypertensive activities of Acepromazine.Approved, Investigational
DoxofyllineAcepromazine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe serum concentration of Acepromazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Acepromazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Illicit
DronedaroneDronedarone may increase the antihypertensive activities of Acepromazine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Acepromazine.Experimental, Illicit
DroxidopaAcepromazine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Acepromazine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Acepromazine.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Acepromazine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Acepromazine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Acepromazine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Acepromazine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Acepromazine is combined with Eperisone.Approved, Investigational
EphedraAcepromazine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineAcepromazine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineAcepromazine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineAcepromazine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acepromazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Acepromazine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Acepromazine.Experimental
EscitalopramEscitalopram may increase the antihypertensive activities of Acepromazine.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Acepromazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Acepromazine.Approved, Investigational
EtafedrineAcepromazine may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Acepromazine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Acepromazine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Acepromazine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Acepromazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Etifoxine.Investigational, Withdrawn
EtilefrineAcepromazine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Acepromazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Acepromazine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Acepromazine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Acepromazine.Approved
FelodipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Acepromazine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Acepromazine is combined with Fendiline.Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoterolAcepromazine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Acepromazine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Acepromazine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Acepromazine is combined with Fish oil.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Acepromazine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Acepromazine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Acepromazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Acepromazine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Acepromazine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Acepromazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Acepromazine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Acepromazine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluvoxamine.Approved, Investigational
FormoterolAcepromazine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Acepromazine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Acepromazine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Acepromazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Acepromazine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Acepromazine.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Acepromazine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Acepromazine.Approved, Illicit, Investigational
GepefrineAcepromazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Acepromazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Acepromazine.Approved, Illicit
GuanabenzAcepromazine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Acepromazine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Acepromazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Acepromazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Acepromazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Acepromazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Acepromazine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Acepromazine.Approved
HexoprenalineAcepromazine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineAcepromazine may decrease the vasoconstricting activities of Higenamine.Investigational
HydrocodoneAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Acepromazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetamineAcepromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Acepromazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved
IloperidoneAcepromazine may increase the antihypertensive activities of Iloperidone.Approved
ImipramineImipramine may increase the antihypertensive activities of Acepromazine.Approved
IndacaterolAcepromazine may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Acepromazine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Acepromazine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Acepromazine.Withdrawn
Iofetamine I-123Acepromazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe therapeutic efficacy of Acepromazine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineAcepromazine may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Acepromazine.Approved, Vet Approved
IsomethepteneAcepromazine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineAcepromazine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineAcepromazine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Isradipine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Acepromazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Acepromazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ketobemidone.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Acepromazine.Approved
LacidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Acepromazine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Acepromazine.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Acepromazine.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
LevobunololAcepromazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Acepromazine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Acepromazine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Acepromazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Acepromazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Acepromazine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Acepromazine.Approved
LevosalbutamolAcepromazine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Acepromazine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Acepromazine.Approved, Investigational
LisdexamfetamineAcepromazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Acepromazine.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Acepromazine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Acepromazine can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Acepromazine is combined with Loperamide.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Acepromazine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Acepromazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Acepromazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Acepromazine.Approved
LumefantrineThe serum concentration of Acepromazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Acepromazine.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe therapeutic efficacy of Acepromazine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Acepromazine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Acepromazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Acepromazine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Acepromazine can be increased when it is combined with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Acepromazine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Acepromazine is combined with Menthol.Approved
MephedroneAcepromazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAcepromazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Acepromazine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Acepromazine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Meptazinol.Experimental
MequitazineAcepromazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Acepromazine.Approved, Investigational
MetaraminolAcepromazine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Acepromazine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Acepromazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Acepromazine.Approved, Illicit
MethamphetamineAcepromazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Acepromazine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Acepromazine.Approved
MethotrimeprazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineAcepromazine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Acepromazine.Approved, Investigational, Vet Approved
MethoxyphenamineAcepromazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Acepromazine.Approved
MethyldopaAcepromazine may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Acepromazine.Approved
MetipranololAcepromazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
MetyrosineAcepromazine may increase the sedative activities of Metyrosine.Approved
MibefradilThe risk or severity of hypotension can be increased when Acepromazine is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine.Approved, Illicit
MidodrineAcepromazine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineAcepromazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Acepromazine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Investigational
MirabegronAcepromazine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Acepromazine.Investigational
MirtazapineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Acepromazine can be increased when it is combined with Mizoribine.Investigational
MMDAAcepromazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Acepromazine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Acepromazine.Approved, Investigational
MoxonidineAcepromazine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Acepromazine is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Acepromazine.Approved
NaphazolineAcepromazine may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Acepromazine.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Acepromazine.Approved, Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Acepromazine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Acepromazine.Approved, Investigational
NicomorphineAcepromazine may increase the hypotensive activities of Nicomorphine.Experimental
NifedipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nifedipine.Approved
NiguldipineAcepromazine may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Acepromazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Acepromazine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Acepromazine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Nordazepam.Approved
NorepinephrineAcepromazine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineAcepromazine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the antihypertensive activities of Acepromazine.Approved
NylidrinAcepromazine may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineAcepromazine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineOlanzapine may increase the antihypertensive activities of Acepromazine.Approved, Investigational
OlodaterolAcepromazine may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acepromazine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Acepromazine.Approved
OpiumThe risk or severity of adverse effects can be increased when Acepromazine is combined with Opium.Approved, Illicit
OrciprenalineAcepromazine may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Acepromazine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Acepromazine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Acepromazine.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Acepromazine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Acepromazine.Approved, Illicit, Investigational
OxyfedrineAcepromazine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineAcepromazine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Acepromazine.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may increase the antihypertensive activities of Acepromazine.Approved
ParaldehydeAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Acepromazine.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Acepromazine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Perazine.Approved, Investigational
PergolideAcepromazine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Acepromazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Acepromazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Acepromazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Phenazocine.Experimental
PhendimetrazineAcepromazine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acepromazine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Acepromazine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Acepromazine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Acepromazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Phenoxyethanol.Approved
PhentermineAcepromazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the antihypertensive activities of Acepromazine.Approved
PhenylephrineAcepromazine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineAcepromazine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Acepromazine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Acepromazine.Approved
PinaveriumThe risk or severity of hypotension can be increased when Acepromazine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pipamperone.Approved, Investigational
PiperaquineThe serum concentration of Acepromazine can be increased when it is combined with Piperaquine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Acepromazine.Approved, Investigational
PirbuterolAcepromazine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Acepromazine is combined with Piritramide.Approved, Investigational
PizotifenAcepromazine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Acepromazine.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Acepromazine.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
PramipexoleAcepromazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Acepromazine.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Acepromazine.Approved
PregabalinThe therapeutic efficacy of Acepromazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolAcepromazine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Acepromazine is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Acepromazine.Approved
PrimaquineThe serum concentration of Acepromazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Acepromazine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Acepromazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Acepromazine.Approved, Investigational
ProcaterolAcepromazine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acepromazine.Approved, Vet Approved
ProguanilThe serum concentration of Acepromazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Acepromazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Acepromazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Acepromazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Acepromazine.Approved, Vet Approved
PropericiazineAcepromazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Acepromazine.Approved
PropiverineAcepromazine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Acepromazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Investigational
ProtokylolAcepromazine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Acepromazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Acepromazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Acepromazine is combined with PSD502.Investigational
PseudoephedrineAcepromazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Acepromazine can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Acepromazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Acepromazine.Approved, Illicit
QuetiapineQuetiapine may increase the antihypertensive activities of Acepromazine.Approved
QuinacrineThe serum concentration of Acepromazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Acepromazine.Approved, Investigational
QuinidineAcepromazine may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineThe serum concentration of Acepromazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Quinisocaine.Experimental
RacepinephrineAcepromazine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Acepromazine is combined with Raclopride.Investigational
RactopamineAcepromazine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe serum concentration of Acepromazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Acepromazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acepromazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acepromazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine.Approved, Withdrawn
ReproterolAcepromazine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Acepromazine.Approved, Investigational
RilmenidineAcepromazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolAcepromazine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Acepromazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ritanserin.Investigational
RitobegronAcepromazine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineAcepromazine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Acepromazine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Romifidine.Vet Approved
RopiniroleAcepromazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Acepromazine.Approved
RotigotineAcepromazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Acepromazine.Approved
SalbutamolAcepromazine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolAcepromazine may decrease the vasoconstricting activities of Salmeterol.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Acepromazine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Acepromazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Acepromazine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Acepromazine is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acepromazine.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Acepromazine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Acepromazine.Approved
SinefunginThe serum concentration of Acepromazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved
SolabegronAcepromazine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Acepromazine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Acepromazine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine.Approved, Investigational
SulfadoxineThe serum concentration of Acepromazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Acepromazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideAcepromazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Acepromazine.Approved, Investigational
SuvorexantAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineAcepromazine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Acepromazine.Approved, Investigational
TafenoquineThe serum concentration of Acepromazine can be increased when it is combined with Tafenoquine.Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Acepromazine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Acepromazine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Acepromazine.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Acepromazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Acepromazine.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Acepromazine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Acepromazine.Approved
TerodilineThe risk or severity of hypotension can be increased when Acepromazine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Acepromazine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Acepromazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrodotoxin.Investigational
TetryzolineAcepromazine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Acepromazine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Acepromazine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Acepromazine is combined with Thiopental.Approved, Vet Approved
ThioproperazineAcepromazine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Acepromazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Acepromazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Acepromazine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Acepromazine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Acepromazine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Acepromazine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Acepromazine is combined with Tolfenamic Acid.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Acepromazine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Acepromazine.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Acepromazine is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Acepromazine.Approved, Investigational
TretoquinolAcepromazine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Acepromazine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Acepromazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Acepromazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Acepromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Acepromazine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Acepromazine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Acepromazine is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Acepromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the antihypertensive activities of Acepromazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Acepromazine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TulobuterolAcepromazine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Acepromazine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Acepromazine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Acepromazine.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Acepromazine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Acepromazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Acepromazine is combined with Veralipride.Experimental
VerapamilAcepromazine may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Acepromazine.Approved
VilanterolAcepromazine may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Acepromazine is combined with Vilazodone.Approved
VinpocetineThe risk or severity of hypotension can be increased when Acepromazine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Acepromazine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Acepromazine is combined with WIN 55212-2.Experimental
XamoterolAcepromazine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Acepromazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Xylazine.Vet Approved
XylometazolineAcepromazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Acepromazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Acepromazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Acepromazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Acepromazine.Approved, Investigational
ZolpidemAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Acepromazine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Acepromazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Acepromazine.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food to reduce irritation

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015552
KEGG Drug
D02604
PubChem Compound
6077
PubChem Substance
46508205
ChemSpider
5852
BindingDB
50131719
ChEBI
44932
ChEMBL
CHEMBL39560
PharmGKB
PA164783999
HET
PMZ
Wikipedia
Acepromazine
ATC Codes
N05AA04 — Acepromazine
PDB Entries
1lvj

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)230 °C at 5.00E-01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0098 mg/mLALOGPS
logP4.32ALOGPS
logP3.49ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)16.06ChemAxon
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.35 m3·mol-1ChemAxon
Polarizability37.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9852
Blood Brain Barrier+0.9844
Caco-2 permeable+0.8203
P-glycoprotein substrateSubstrate0.8092
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.857
Renal organic cation transporterInhibitor0.7087
CYP450 2C9 substrateNon-substrate0.7438
CYP450 2D6 substrateSubstrate0.8618
CYP450 3A4 substrateSubstrate0.6468
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9319
CYP450 2D6 inhibitorInhibitor0.9115
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9105
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7333
Ames testNon AMES toxic0.849
CarcinogenicityNon-carcinogens0.9292
BiodegradationNot ready biodegradable0.9829
Rat acute toxicity2.7963 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9537
hERG inhibition (predictor II)Inhibitor0.7813
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.84 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9110000000-bd29071c9502d119fa54
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0009000000-ba8f0be449800ec10cf1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002r-9025000000-028fcf239ba77c5d26d0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-9060000000-33b3210f75c9aa6899f3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0abi-9180000000-9b10f7d22435e199c283
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9670000000-0c65cbf1672ae4899236

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Acetophenones / Aryl alkyl ketones / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Acetophenone / Aryl thioether / Tertiary aliphatic/aromatic amine / Aryl alkyl ketone / Aryl ketone / Para-thiazine / Benzenoid
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amino compound, methyl ketone, aromatic ketone (CHEBI:44932)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  3. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263]
  4. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134]
  2. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]

Drug created on August 29, 2007 14:12 / Updated on July 02, 2018 20:48